JITC

Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models
Manali S Phadke, Jiannong Li, Zhihua Chen, Paulo C Rodriguez, Jessica K Mandula, Lilit Karapetyan, Peter A Forsyth, Y Ann Chen, Keiran S M Smalley

Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e007239; DOI: 10.1136/jitc-2023-007239
Brave new world of cfDNA-omics for early cancer detection
Christian Rolfo, Alessandro Russo

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e006309; DOI: 10.1136/jitc-2022-006309
Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics
Catherine M Ade, Matthew J Sporn, Sudipto Das, Zhiya Yu, Ken-ichi Hanada, Yue A Qi, Tapan Maity, Xu Zhang, Udayan Guha, Thorkell Andresson, James C Yang

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007097; DOI: 10.1136/jitc-2023-007097
Siglec-9⁺ tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
Yiying Wang, Mengdi He, Chen Zhang, Kankan Cao, Guodong Zhang, Moran Yang, Yan Huang, Wei Jiang, Haiou Liu

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007099; DOI: 10.1136/jitc-2023-007099
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
Zaki Molvi, Martin G Klatt, Tao Dao, Jessica Urraca, David A Scheinberg, Richard J O'Reilly

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e006889; DOI: 10.1136/jitc-2023-006889
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, Mari Hosonaga, Toru Mukohara, Kiyoshi Yoshimura, Chiyo K Imamura, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka, Kenichi Yoshimura, Toshimi Takano

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007126; DOI: 10.1136/jitc-2023-007126
Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
Chiara Brignole, Enzo Calarco, Veronica Bensa, Elena Giusto, Patrizia Perri, Eleonora Ciampi, Maria Valeria Corrias, Simonetta Astigiano, Michele Cilli, Derik Loo, Ezio Bonvini, Fabio Pastorino, Mirco Ponzoni

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007174; DOI: 10.1136/jitc-2023-007174
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
Vedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, Manar S Shafat, Amaia Cadinanos Garai, Louisa Green, Alastair Hotblack, Fred Arce Vargas, Karl S Peggs, Anniek B van der Waart, Harry Dolstra, Martin A Pule, Claire Roddie

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007002; DOI: 10.1136/jitc-2023-007002
Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
Yuxuan Song, Yun Peng, Caipeng Qin, Yulong Wang, Wenbo Yang, Yiqing Du, Tao Xu

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e006643; DOI: 10.1136/jitc-2022-006643
Complete response to immunotherapy in a patient with high-risk stage III colorectal cancer after ctDNA-guided detection of early adjuvant treatment failure
Nicholas Lucchesi, Jenna M Ally, Matthew J Reilley

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007434; DOI: 10.1136/jitc-2023-007434

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages